Predictus is a BU spin off company that has developed and predictive biomarker for a class of anticancer drug.
P-topoI-Dx is a test that will determine if a cancer patient will respond to topoisomerase I inhibitors.
Pitch
Highlight
Full Interview
Predictus Video
Having trouble signing in?